Welcome to our dedicated page for Monopar Therapeutics news (Ticker: MNPR), a resource for investors and traders seeking the latest updates and insights on Monopar Therapeutics stock.
Monopar Therapeutics Inc. (MNPR) is a clinical-stage biopharmaceutical company whose news flow centers on drug development milestones, scientific data presentations, financial updates, and capital markets activity. Public communications describe a focus on late-stage ALXN1840 for Wilson disease and MNPR-101-based radiopharmaceutical programs for imaging and treating advanced cancers.
News items for Monopar commonly include clinical and scientific results, such as data from the ALXN1840-WD-204 copper balance study and pooled long-term neurological and safety analyses in Wilson disease. The company also reports on presentations at major medical meetings, including the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting and the American Neurological Association (ANA) Annual Meeting, as well as publications in peer-reviewed journals like the Journal of Hepatology.
Investors and observers can also find updates on radiopharmaceutical programs, including progress in Phase 1 imaging and therapeutic trials with MNPR-101-Zr and MNPR-101-Lu, and regulatory developments such as U.S. Food and Drug Administration authorization for an Expanded Access Program in advanced solid tumors. In addition, Monopar issues press releases on financial results, describing quarterly performance, research and development spending, and general and administrative expenses, alongside information on cash resources and capital-raising transactions.
Further topics in Monopar’s news include capital markets events, such as underwritten offerings of common stock and pre-funded warrants, share repurchase agreements with existing stockholders, and inclusion in the Russell 3000 and Russell 2000 indexes. Readers interested in MNPR news can use this page to follow these developments and review how the company describes the evolution of its Wilson disease and radiopharmaceutical programs over time.
Monopar Therapeutics Inc. (Nasdaq: MNPR) announced the presentation of its oropharyngeal cancer (OPC) patient population analysis from the Phase 2 Validive trial at the MASCC/ISOO 2021 annual meeting. This analysis supports the design of the Phase 2b/3 VOICE trial, which is currently recruiting OPC patients in the US. Validive is aimed at preventing severe oral mucositis caused by chemoradiotherapy, with prior Phase 2 results showing a relative incidence reduction of 40% compared to placebo. The presentation will be available on demand beginning June 25, 2021.
Monopar Therapeutics Inc. (Nasdaq: MNPR) announced a collaboration with the Cancer Science Institute of Singapore to evaluate its new drug MNPR-202, designed to treat chemotherapy-resistant cancers. MNPR-202 maintains a potentially non-cardiotoxic structure similar to camsirubicin but is modified to target cancers that resist traditional therapies. This partnership aims to deepen the understanding of MNPR-202’s impact on cancer cells and its potential to enhance immunotherapy treatments. A clinical trial for camsirubicin is set to begin in late 2021.
Monopar Therapeutics Inc. (Nasdaq: MNPR) announced the appointment of Andrew Cittadine as Chief Operating Officer on June 1, 2021. Cittadine brings extensive experience in healthcare, having founded successful companies such as Sensant Corp. and American Biooptics. He will oversee Monopar's global operations and business strategy, contributing to their goal of developing therapeutics for cancer patients. Monopar's pipeline includes Validive, camsirubicin, and the preclinical antibody MNPR-101. CEO Chandler Robinson expressed confidence in Cittadine’s leadership during this pivotal time for the company.
Monopar Therapeutics (MNPR) and NorthStar Medical Radioisotopes have filed a provisional patent for a radiotherapeutic combining Monopar's MNPR-101 antibody with Actinium-225. The Radio-Immuno-Therapeutic (RIT) shows 98% radiochemical purity, indicating potential as an effective treatment for certain cancers and severe COVID-19.
This development may also allow for more efficient production with reduced material use, thus improving supply chain logistics. If granted, the patent could significantly enhance MNPR-101’s patent estate.
Monopar Therapeutics Inc. (MNPR) and NorthStar Medical Radioisotopes have filed a provisional patent for a new approach to improve the efficacy of Actinium-based radiopharmaceuticals. The patent focuses on using PCTA to enhance binding efficiency of Ac-225 to antibodies, showing nearly 100% binding compared to traditional methods. This innovation could lead to increased efficacy, reduced toxicity, and better manufacturing efficiency. The companies aim to explore development and licensing opportunities for this technology, which holds potential to address challenges in cancer treatment.
Monopar Therapeutics Inc. (Nasdaq: MNPR) announced key updates in their latest press release dated May 13, 2021. The company reported the first patient dosed in the Phase 2b/3 VOICE clinical trial for Validive, aimed at preventing severe oral mucositis in cancer patients. They also received patent allowances for Validive and a novel family of camsirubicin analogs. Financially, Monopar holds $25.7 million in cash, though net losses increased to $1.9 million in Q1 2021.
Monopar Therapeutics (Nasdaq: MNPR) announced the publication of a peer-reviewed study demonstrating the potential of its uPA antibody fragment for imaging triple-negative breast cancer. The study suggests that this technology could facilitate rapid PET imaging to identify and monitor uPA overexpression in tumors, which is crucial for treatment decisions. The company is optimistic about leveraging its panel of uPA-targeted antibodies for cancer imaging and treatment development.
Monopar Therapeutics (Nasdaq: MNPR) recently announced key developments and financial results for Q4 and full-year 2020. The company commenced the Phase 2b/3 VOICE clinical trial for Validive, aimed at preventing severe oral mucositis in oropharyngeal cancer patients. A Phase 2 trial for camsirubicin is set to begin in Q2 2021, evaluating its effectiveness against doxorubicin. The company reported a net loss of $6.3 million for 2020, showing an increase from $4.2 million in 2019, with cash reserves of $16.7 million to support operations at least through March 2022.
Monopar Therapeutics Inc. (Nasdaq: MNPR) has announced a collaboration with Andrew Cittadine to explore strategic options for MNPR-101 as an imaging agent in bladder cancer surgeries. Cittadine, a seasoned entrepreneur in medtech, brings a wealth of experience in oncology diagnostics. The partnership aims to leverage MNPR-101's potential following promising early data published in the European Journal of Cancer. The company focuses on developing therapeutics that improve the quality of life for cancer patients, including its pipeline products.
Monopar Therapeutics Inc. (Nasdaq: MNPR), a biopharmaceutical company focused on cancer therapeutics, announced upcoming presentations by CEO Chandler D. Robinson at several investor conferences in March. The presentations include:
- H.C. Wainwright Global Life Sciences Conference on March 9, 2021, at 7:00 a.m. ET.
- 33rd Annual Roth Conference on March 16, 2021, at 12:00 p.m. ET.
- Maxim’s 2021 Emerging Growth Virtual Conference on March 17, 2021, with the timing to be determined.
Monopar develops therapeutics aimed at improving cancer patients' lives.